THERAPY DOSSIER · th-e4e7badf9d27

Recombinant human MG53 protein (rhMG53) encapsulated in a thermosensitive hydrogel

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Wound
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT07094776 ↗Phase not recordedenrolling by invitation

Evaluation of MG53 (TRIM72) Levels in Women With Polycystic Ovary Syndrome: An Observational Study

Polycystic Ovary Syndrome (PCOS) · Insulin Resistance Syndrome

Enrolment: 128 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 26306047 ↗2015Reported benefit

Modulation of wound healing and scar formation by MG53 protein-mediated cell membrane repair.

MixedWoundmg53-/- mice; Sprague-Dawley ratsTopical, in a hydrogel formulation

Model: Dermal injury models in rodents (skin wounding) plus in vitro scratch wounding of fibroblasts and acute injury to keratinocytes

mg53-/- mice showed defective skin architecture, collagen overproduction, delayed wound healing and abnormal scarring despite MG53 being absent from keratinocytes and fibroblasts. Hydrogel-encapsulated recombinant human MG53 accelerated wound healing and reduced scarring in rodent dermal injury mod…

Extraction: extract · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.

Loading the evidence…